Molecular targeted therapies for breast cancer treatment
Open Access
- 24 July 2008
- journal article
- review article
- Published by Springer Science and Business Media LLC in Breast Cancer Research
- Vol. 10 (4), 211
- https://doi.org/10.1186/bcr2112
Abstract
Targeting the oestrogen receptor, HER2 (human epidermal growth factor receptor 2) and vascular endothelial growth factor has markedly improved breast cancer therapy. New targeted therapeutic approaches to induction of apoptosis or inhibition of anti-apoptosis, cell cycle progression, signal transduction and angiogenesis are described. The molecular pathways and their inhibitory or repair mechanisms are discussed in the preclinical and clinical settings.This publication has 79 references indexed in Scilit:
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerThe New England Journal of Medicine, 2007
- Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: Focus on clinical trials and perspectivesCritical Reviews in Oncology/Hematology, 2007
- Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancerBreast Cancer Research, 2007
- Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activityProceedings of the National Academy of Sciences of the United States of America, 2007
- Enhanced NFκB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancerBMC Cancer, 2007
- Targeting tumor-associated macrophages as a novel strategy against breast cancerJCI Insight, 2006
- A nonreplicating adenoviral vector that contains the wild-typep53 transgene combined with chemotherapy for primary breast cancerCancer, 2006
- Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1Annals of Oncology, 2006
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerThe New England Journal of Medicine, 2005
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993